NASDAQ: BLUEBluebird Bio Inc Stock
$4.14-0.01 (-0.24%)
Updated Apr 17, 2025
BLUE Price
$4.14
Fair Value Price
N/A
Market Cap
$40.53M
52 Week Low
$3.56
52 Week High
$28.60
P/E
-0.17x
P/B
-1.29x
P/S
0.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$83.81M
Earnings
-$240.72M
Gross Margin
-6.6%
Operating Margin
-260.2%
Profit Margin
-287.2%
Debt to Equity
-15.6
Operating Cash Flow
-$260M
Beta
1.45
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BLUE Overview
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLUE's potential to beat the market
- BLUE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BLUE
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important BLUE news, forecast changes, insider trades & much more!
BLUE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLUE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLUE is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLUE is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BLUE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BLUE due diligence checks available for Premium users.
Valuation
BLUE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
-177.72x
Market
27.98x
BLUE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.29x
Industry
4.05x
BLUE's financial health
Profit margin
Revenue
$38.5M
Net Income
-$28.7M
Profit Margin
-74.5%
BLUE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
BLUE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$460.2M
Liabilities
$491.8M
Debt to equity
-15.6
BLUE's short-term liabilities ($321.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLUE's long-term liabilities ($170.30M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLUE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BLUE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$50.2M
Investing
$2.5M
Financing
$35.0M
BLUE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BLUE vs Biotech Stocks
Bluebird Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.